# Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

> **NCT06258642** · NA · RECRUITING · sponsor: **Fudan University** · enrollment: 39 (estimated)

## Conditions studied

- Small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** Irinotecan Liposome
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT06258642
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-17
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06258642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06258642, "Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06258642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*